The Bangalore-based biopharmaceuticals firm Biocon on July 23, 2015 has announced the appointment of Dr Narendra Chirmule as the head of R&D in place of Dr Abhijit Barve, who has moved back to the US for personal reasons.
Dr Chirmule held senior leadership positions at Amgen and Merck in the US, in the departments of Clinical Immunology overseeing drug development for regulated markets. He has deep expertise in the area of immunogenicity in biologics and has been involved in shaping the regulatory guidelines for biologics and biosimilars in EU & US. He holds a Ph D from Cancer Research Institute, University of Mumbai, with post-doctoral training at Cornell University Medical College, and has teaching and research experience as an Assistant Professor in the Human Gene Therapy Group of University of Pennsylvania.
Dr Chirmule held senior leadership positions at Amgen and Merck in the US, in the departments of Clinical Immunology overseeing drug development for regulated markets. He has deep expertise in the area of immunogenicity in biologics and has been involved in shaping the regulatory guidelines for biologics and biosimilars in EU & US. He holds a Ph D from Cancer Research Institute, University of Mumbai, with post-doctoral training at Cornell University Medical College, and has teaching and research experience as an Assistant Professor in the Human Gene Therapy Group of University of Pennsylvania.